Specialty  ||| S:0 E:10 ||| NN
pharmacies  ||| S:10 E:21 ||| NNS
and  ||| S:21 E:25 ||| CC
other  ||| S:25 E:31 ||| JJ
restricted  ||| S:31 E:42 ||| JJ
drug  ||| S:42 E:47 ||| NN
distribution  ||| S:47 E:60 ||| NN
systems ||| S:60 E:67 ||| NNS
:  ||| S:67 E:69 ||| :
financial  ||| S:69 E:79 ||| JJ
and  ||| S:79 E:83 ||| CC
safety  ||| S:83 E:90 ||| NN
considerations  ||| S:90 E:105 ||| NNS
for  ||| S:105 E:109 ||| IN
patients  ||| S:109 E:118 ||| NNS
and  ||| S:118 E:122 ||| CC
health-system  ||| S:122 E:136 ||| JJ
pharmacists  ||| S:136 E:148 ||| NNS
To  ||| S:148 E:151 ||| TO
discuss  ||| S:151 E:159 ||| VB
the  ||| S:159 E:163 ||| DT
role  ||| S:163 E:168 ||| NN
of  ||| S:168 E:171 ||| IN
restricted  ||| S:171 E:182 ||| JJ
drug  ||| S:182 E:187 ||| NN
distribution  ||| S:187 E:200 ||| NN
systems  ||| S:200 E:208 ||| NNS
in  ||| S:208 E:211 ||| IN
the  ||| S:211 E:215 ||| DT
implementation  ||| S:215 E:230 ||| NN
of  ||| S:230 E:233 ||| IN
risk  ||| S:233 E:238 ||| NN
evaluation  ||| S:238 E:249 ||| NN
and  ||| S:249 E:253 ||| CC
mitigation  ||| S:253 E:264 ||| JJ
strategies  ||| S:264 E:275 ||| NNS
( ||| S:275 E:276 ||| -LRB-
REMS ||| S:276 E:280 ||| NNP
) ||| S:280 E:281 ||| -RRB-
,  ||| S:281 E:283 ||| ,
health-system  ||| S:283 E:297 ||| JJ
pharmacists ||| S:297 E:308 ||| NN
'  ||| S:308 E:310 ||| POS
concerns  ||| S:310 E:319 ||| NNS
associated  ||| S:319 E:330 ||| VBN
with  ||| S:330 E:335 ||| IN
the  ||| S:335 E:339 ||| DT
use  ||| S:339 E:343 ||| NN
of  ||| S:343 E:346 ||| IN
specialty  ||| S:346 E:356 ||| NN
pharmacies  ||| S:356 E:367 ||| NNS
and  ||| S:367 E:371 ||| CC
other  ||| S:371 E:377 ||| JJ
restricted  ||| S:377 E:388 ||| JJ
drug  ||| S:388 E:393 ||| NN
distribution  ||| S:393 E:406 ||| NN
systems ||| S:406 E:413 ||| NNS
,  ||| S:413 E:415 ||| ,
reimbursement  ||| S:415 E:429 ||| JJ
policies  ||| S:429 E:438 ||| NNS
for  ||| S:438 E:442 ||| IN
high-cost  ||| S:442 E:452 ||| JJ
specialty  ||| S:452 E:462 ||| NN
drugs ||| S:462 E:467 ||| NNS
,  ||| S:467 E:469 ||| ,
supply  ||| S:469 E:476 ||| NN
chain  ||| S:476 E:482 ||| NN
models  ||| S:482 E:489 ||| NNS
for  ||| S:489 E:493 ||| IN
traditional  ||| S:493 E:505 ||| JJ
and  ||| S:505 E:509 ||| CC
specialty  ||| S:509 E:519 ||| NN
drugs ||| S:519 E:524 ||| NNS
,  ||| S:524 E:526 ||| ,
and  ||| S:526 E:530 ||| CC
emerging  ||| S:530 E:539 ||| VBG
trends  ||| S:539 E:546 ||| NNS
in  ||| S:546 E:549 ||| IN
the  ||| S:549 E:553 ||| DT
management  ||| S:553 E:564 ||| NN
of  ||| S:564 E:567 ||| IN
and  ||| S:567 E:571 ||| CC
reimbursement  ||| S:571 E:585 ||| NN
for  ||| S:585 E:589 ||| IN
specialty  ||| S:589 E:599 ||| NN
pharmaceuticals ||| S:599 E:614 ||| NNS
.  ||| S:614 E:616 ||| .
Restricted  ||| S:616 E:627 ||| JJ
drug  ||| S:627 E:632 ||| NN
distribution  ||| S:632 E:645 ||| NN
systems  ||| S:645 E:653 ||| NNS
established  ||| S:653 E:665 ||| VBN
by  ||| S:665 E:668 ||| IN
pharmaceutical  ||| S:668 E:683 ||| JJ
manufacturers ||| S:683 E:696 ||| NNS
,  ||| S:696 E:698 ||| ,
specialty  ||| S:698 E:708 ||| NN
pharmacies ||| S:708 E:718 ||| NNS
,  ||| S:718 E:720 ||| ,
or  ||| S:720 E:723 ||| CC
other  ||| S:723 E:729 ||| JJ
specialty  ||| S:729 E:739 ||| NN
suppliers  ||| S:739 E:749 ||| NNS
may  ||| S:749 E:753 ||| MD
be  ||| S:753 E:756 ||| VB
a  ||| S:756 E:758 ||| DT
component  ||| S:758 E:768 ||| NN
of  ||| S:768 E:771 ||| IN
REMS ||| S:771 E:775 ||| NNP
,  ||| S:775 E:777 ||| ,
which  ||| S:777 E:783 ||| WDT
are  ||| S:783 E:787 ||| VBP
required  ||| S:787 E:796 ||| VBN
by  ||| S:796 E:799 ||| IN
the  ||| S:799 E:803 ||| DT
Food  ||| S:803 E:808 ||| NNP
and  ||| S:808 E:812 ||| CC
Drug  ||| S:812 E:817 ||| NNP
Administration  ||| S:817 E:832 ||| NNP
for  ||| S:832 E:836 ||| IN
the  ||| S:836 E:840 ||| DT
management  ||| S:840 E:851 ||| NN
of  ||| S:851 E:854 ||| IN
known  ||| S:854 E:860 ||| VBN
or  ||| S:860 E:863 ||| CC
potential  ||| S:863 E:873 ||| JJ
serious  ||| S:873 E:881 ||| JJ
risks  ||| S:881 E:887 ||| NNS
from  ||| S:887 E:892 ||| IN
certain  ||| S:892 E:900 ||| JJ
drugs ||| S:900 E:905 ||| NNS
.  ||| S:905 E:907 ||| .
Concerns  ||| S:907 E:916 ||| NNS
of  ||| S:916 E:919 ||| IN
health-system  ||| S:919 E:933 ||| JJ
pharmacists  ||| S:933 E:945 ||| NNS
using  ||| S:945 E:951 ||| VBG
specialty  ||| S:951 E:961 ||| NN
suppliers  ||| S:961 E:971 ||| NNS
include  ||| S:971 E:979 ||| VBP
access  ||| S:979 E:986 ||| NN
to  ||| S:986 E:989 ||| TO
pharmaceuticals ||| S:989 E:1004 ||| NNS
,  ||| S:1004 E:1006 ||| ,
operational  ||| S:1006 E:1018 ||| JJ
challenges ||| S:1018 E:1028 ||| NNS
,  ||| S:1028 E:1030 ||| ,
product  ||| S:1030 E:1038 ||| NN
integrity ||| S:1038 E:1047 ||| NN
,  ||| S:1047 E:1049 ||| ,
financial  ||| S:1049 E:1059 ||| JJ
implications ||| S:1059 E:1071 ||| NNS
,  ||| S:1071 E:1073 ||| ,
continuity  ||| S:1073 E:1084 ||| NN
of  ||| S:1084 E:1087 ||| IN
care ||| S:1087 E:1091 ||| NN
,  ||| S:1091 E:1093 ||| ,
and  ||| S:1093 E:1097 ||| CC
patient  ||| S:1097 E:1105 ||| JJ
safety ||| S:1105 E:1111 ||| NN
.  ||| S:1111 E:1113 ||| .
An  ||| S:1113 E:1116 ||| DT
ambulatory  ||| S:1116 E:1127 ||| JJ
care  ||| S:1127 E:1132 ||| NN
patient  ||| S:1132 E:1140 ||| NN
taking  ||| S:1140 E:1147 ||| VBG
a  ||| S:1147 E:1149 ||| DT
specialty  ||| S:1149 E:1159 ||| NN
drug  ||| S:1159 E:1164 ||| NN
product  ||| S:1164 E:1172 ||| NN
from  ||| S:1172 E:1177 ||| IN
home  ||| S:1177 E:1182 ||| NN
to  ||| S:1182 E:1185 ||| TO
a  ||| S:1185 E:1187 ||| DT
hospital  ||| S:1187 E:1196 ||| NN
outpatient  ||| S:1196 E:1207 ||| NN
clinic  ||| S:1207 E:1214 ||| NN
or  ||| S:1214 E:1217 ||| CC
inpatient  ||| S:1217 E:1227 ||| JJ
setting  ||| S:1227 E:1235 ||| NN
for  ||| S:1235 E:1239 ||| IN
administration ||| S:1239 E:1253 ||| NN
,  ||| S:1253 E:1255 ||| ,
a  ||| S:1255 E:1257 ||| DT
practice  ||| S:1257 E:1266 ||| NN
known  ||| S:1266 E:1272 ||| VBN
as  ||| S:1272 E:1275 ||| IN
brown  ||| S:1275 E:1281 ||| JJ
bagging ||| S:1281 E:1288 ||| NN
,  ||| S:1288 E:1290 ||| ,
raises  ||| S:1290 E:1297 ||| VBZ
concerns  ||| S:1297 E:1306 ||| NNS
about  ||| S:1306 E:1312 ||| IN
product  ||| S:1312 E:1320 ||| NN
integrity  ||| S:1320 E:1330 ||| NN
and  ||| S:1330 E:1334 ||| CC
institutional  ||| S:1334 E:1348 ||| JJ
liability ||| S:1348 E:1357 ||| NN
.  ||| S:1357 E:1359 ||| .
An  ||| S:1359 E:1362 ||| DT
institution ||| S:1362 E:1373 ||| NN
's  ||| S:1373 E:1376 ||| POS
finances ||| S:1376 E:1384 ||| NNS
,  ||| S:1384 E:1386 ||| ,
tolerance  ||| S:1386 E:1396 ||| NN
for  ||| S:1396 E:1400 ||| IN
liability ||| S:1400 E:1409 ||| NN
,  ||| S:1409 E:1411 ||| ,
and  ||| S:1411 E:1415 ||| CC
ability  ||| S:1415 E:1423 ||| NN
to  ||| S:1423 E:1426 ||| TO
skillfully  ||| S:1426 E:1437 ||| VB
manage  ||| S:1437 E:1444 ||| VB
the  ||| S:1444 E:1448 ||| DT
processes  ||| S:1448 E:1458 ||| VBZ
involved  ||| S:1458 E:1467 ||| VBN
often  ||| S:1467 E:1473 ||| RB
determine  ||| S:1473 E:1483 ||| VB
its  ||| S:1483 E:1487 ||| PRP$
choice  ||| S:1487 E:1494 ||| NN
between  ||| S:1494 E:1502 ||| IN
an  ||| S:1502 E:1505 ||| DT
approach  ||| S:1505 E:1514 ||| NN
that  ||| S:1514 E:1519 ||| WDT
prohibits  ||| S:1519 E:1529 ||| VBZ
brown  ||| S:1529 E:1535 ||| JJ
bagging  ||| S:1535 E:1543 ||| NN
but  ||| S:1543 E:1547 ||| CC
is  ||| S:1547 E:1550 ||| VBZ
costly  ||| S:1550 E:1557 ||| JJ
and  ||| S:1557 E:1561 ||| CC
one  ||| S:1561 E:1565 ||| CD
that  ||| S:1565 E:1570 ||| WDT
permits  ||| S:1570 E:1578 ||| VBZ
the  ||| S:1578 E:1582 ||| DT
practice  ||| S:1582 E:1591 ||| NN
under  ||| S:1591 E:1597 ||| IN
certain  ||| S:1597 E:1605 ||| JJ
conditions  ||| S:1605 E:1616 ||| NNS
and  ||| S:1616 E:1620 ||| CC
is  ||| S:1620 E:1623 ||| VBZ
less  ||| S:1623 E:1628 ||| RBR
costly ||| S:1628 E:1634 ||| JJ
.  ||| S:1634 E:1636 ||| .
The  ||| S:1636 E:1640 ||| DT
recent  ||| S:1640 E:1647 ||| JJ
shift  ||| S:1647 E:1653 ||| NN
from  ||| S:1653 E:1658 ||| IN
a  ||| S:1658 E:1660 ||| DT
traditional  ||| S:1660 E:1672 ||| JJ
supply  ||| S:1672 E:1679 ||| NN
chain  ||| S:1679 E:1685 ||| NN
model  ||| S:1685 E:1691 ||| NN
to  ||| S:1691 E:1694 ||| TO
a  ||| S:1694 E:1696 ||| DT
specialty  ||| S:1696 E:1706 ||| NN
pharmacy  ||| S:1706 E:1715 ||| NN
supply  ||| S:1715 E:1722 ||| NN
chain  ||| S:1722 E:1728 ||| NN
model  ||| S:1728 E:1734 ||| NN
for  ||| S:1734 E:1738 ||| IN
high-cost  ||| S:1738 E:1748 ||| JJ
pharmaceuticals  ||| S:1748 E:1764 ||| NNS
has  ||| S:1764 E:1768 ||| VBZ
the  ||| S:1768 E:1772 ||| DT
potential  ||| S:1772 E:1782 ||| JJ
to  ||| S:1782 E:1785 ||| TO
increase  ||| S:1785 E:1794 ||| VB
pharmaceutical  ||| S:1794 E:1809 ||| JJ
costs  ||| S:1809 E:1815 ||| NNS
for  ||| S:1815 E:1819 ||| IN
health  ||| S:1819 E:1826 ||| NN
systems ||| S:1826 E:1833 ||| NNS
.  ||| S:1833 E:1835 ||| .
A  ||| S:1835 E:1837 ||| DT
dialogue  ||| S:1837 E:1846 ||| NN
is  ||| S:1846 E:1849 ||| VBZ
needed  ||| S:1849 E:1856 ||| VBN
between  ||| S:1856 E:1864 ||| IN
health-system  ||| S:1864 E:1878 ||| JJ
pharmacists  ||| S:1878 E:1890 ||| NNS
and  ||| S:1890 E:1894 ||| CC
group  ||| S:1894 E:1900 ||| NN
purchasing  ||| S:1900 E:1911 ||| NN
organizations  ||| S:1911 E:1925 ||| NNS
to  ||| S:1925 E:1928 ||| TO
address  ||| S:1928 E:1936 ||| VB
the  ||| S:1936 E:1940 ||| DT
latter ||| S:1940 E:1946 ||| NN
's  ||| S:1946 E:1949 ||| POS
role  ||| S:1949 E:1954 ||| NN
in  ||| S:1954 E:1957 ||| IN
mitigating  ||| S:1957 E:1968 ||| VBG
the  ||| S:1968 E:1972 ||| DT
financial  ||| S:1972 E:1982 ||| JJ
implications  ||| S:1982 E:1995 ||| NNS
of  ||| S:1995 E:1998 ||| IN
this  ||| S:1998 E:2003 ||| DT
change  ||| S:2003 E:2010 ||| NN
and  ||| S:2010 E:2014 ||| CC
to  ||| S:2014 E:2017 ||| TO
help  ||| S:2017 E:2022 ||| VB
clarify  ||| S:2022 E:2030 ||| VB
the  ||| S:2030 E:2034 ||| DT
safety  ||| S:2034 E:2041 ||| NN
issues ||| S:2041 E:2047 ||| NNS
.  ||| S:2047 E:2049 ||| .
Some  ||| S:2049 E:2054 ||| DT
health  ||| S:2054 E:2061 ||| NN
plans  ||| S:2061 E:2067 ||| NNS
have  ||| S:2067 E:2072 ||| VBP
shifted  ||| S:2072 E:2080 ||| VBN
part  ||| S:2080 E:2085 ||| NN
of  ||| S:2085 E:2088 ||| IN
the  ||| S:2088 E:2092 ||| DT
cost  ||| S:2092 E:2097 ||| NN
of  ||| S:2097 E:2100 ||| IN
expensive  ||| S:2100 E:2110 ||| JJ
drugs  ||| S:2110 E:2116 ||| NNS
to  ||| S:2116 E:2119 ||| TO
patients  ||| S:2119 E:2128 ||| NNS
by  ||| S:2128 E:2131 ||| IN
establishing  ||| S:2131 E:2144 ||| VBG
a  ||| S:2144 E:2146 ||| DT
fourth  ||| S:2146 E:2153 ||| JJ
tier  ||| S:2153 E:2158 ||| NN
of  ||| S:2158 E:2161 ||| IN
drugs  ||| S:2161 E:2167 ||| NNS
with  ||| S:2167 E:2172 ||| IN
a  ||| S:2172 E:2174 ||| DT
large  ||| S:2174 E:2180 ||| JJ
copayment  ||| S:2180 E:2190 ||| NNS
based  ||| S:2190 E:2196 ||| VBN
on  ||| S:2196 E:2199 ||| IN
a  ||| S:2199 E:2201 ||| DT
substantial  ||| S:2201 E:2213 ||| JJ
percentage  ||| S:2213 E:2224 ||| NN
of  ||| S:2224 E:2227 ||| IN
the  ||| S:2227 E:2231 ||| DT
cost  ||| S:2231 E:2236 ||| NN
of  ||| S:2236 E:2239 ||| IN
the  ||| S:2239 E:2243 ||| DT
drug ||| S:2243 E:2247 ||| NN
.  ||| S:2247 E:2249 ||| .
The  ||| S:2249 E:2253 ||| DT
number  ||| S:2253 E:2260 ||| NN
and  ||| S:2260 E:2264 ||| CC
cost  ||| S:2264 E:2269 ||| NN
of  ||| S:2269 E:2272 ||| IN
specialty  ||| S:2272 E:2282 ||| NN
drugs  ||| S:2282 E:2288 ||| NNS
are  ||| S:2288 E:2292 ||| VBP
expected  ||| S:2292 E:2301 ||| VBN
to  ||| S:2301 E:2304 ||| TO
increase  ||| S:2304 E:2313 ||| VB
in  ||| S:2313 E:2316 ||| IN
the  ||| S:2316 E:2320 ||| DT
future ||| S:2320 E:2326 ||| NN
.  ||| S:2326 E:2328 ||| .
New  ||| S:2328 E:2332 ||| JJ
approaches  ||| S:2332 E:2343 ||| NNS
and  ||| S:2343 E:2347 ||| CC
reimbursement  ||| S:2347 E:2361 ||| JJ
models  ||| S:2361 E:2368 ||| NNS
are  ||| S:2368 E:2372 ||| VBP
emerging  ||| S:2372 E:2381 ||| VBG
to  ||| S:2381 E:2384 ||| TO
manage  ||| S:2384 E:2391 ||| VB
the  ||| S:2391 E:2395 ||| DT
high  ||| S:2395 E:2400 ||| JJ
cost  ||| S:2400 E:2405 ||| NN
of  ||| S:2405 E:2408 ||| IN
new  ||| S:2408 E:2412 ||| JJ
pharmaceuticals ||| S:2412 E:2427 ||| NNS
.  ||| S:2427 E:2429 ||| .
Health-system  ||| S:2429 E:2443 ||| JJ
pharmacists  ||| S:2443 E:2455 ||| NNS
can  ||| S:2455 E:2459 ||| MD
improve  ||| S:2459 E:2467 ||| VB
drug  ||| S:2467 E:2472 ||| NN
safety  ||| S:2472 E:2479 ||| NN
and  ||| S:2479 E:2483 ||| CC
manage  ||| S:2483 E:2490 ||| VB
costs  ||| S:2490 E:2496 ||| NNS
by  ||| S:2496 E:2499 ||| IN
collaborating  ||| S:2499 E:2513 ||| VBG
with  ||| S:2513 E:2518 ||| IN
group  ||| S:2518 E:2524 ||| NN
purchasing  ||| S:2524 E:2535 ||| NN
organizations ||| S:2535 E:2548 ||| NNS
,  ||| S:2548 E:2550 ||| ,
establishing  ||| S:2550 E:2563 ||| VBG
policies  ||| S:2563 E:2572 ||| NNS
for  ||| S:2572 E:2576 ||| IN
brown  ||| S:2576 E:2582 ||| JJ
bagging ||| S:2582 E:2589 ||| NN
,  ||| S:2589 E:2591 ||| ,
and  ||| S:2591 E:2595 ||| CC
making  ||| S:2595 E:2602 ||| VBG
efforts  ||| S:2602 E:2610 ||| NNS
to  ||| S:2610 E:2613 ||| TO
reconcile  ||| S:2613 E:2623 ||| VB
drug  ||| S:2623 E:2628 ||| NN
therapy  ||| S:2628 E:2636 ||| NN
provided  ||| S:2636 E:2645 ||| VBN
in  ||| S:2645 E:2648 ||| IN
different  ||| S:2648 E:2658 ||| JJ
settings  ||| S:2658 E:2667 ||| NNS
through  ||| S:2667 E:2675 ||| IN
traditional  ||| S:2675 E:2687 ||| JJ
drug  ||| S:2687 E:2692 ||| NN
channels  ||| S:2692 E:2701 ||| NNS
and  ||| S:2701 E:2705 ||| CC
specialty  ||| S:2705 E:2715 ||| NN
pharmacies  ||| S:2715 E:2726 ||| NNS
or  ||| S:2726 E:2729 ||| CC
other  ||| S:2729 E:2735 ||| JJ
restricted  ||| S:2735 E:2746 ||| JJ
drug  ||| S:2746 E:2751 ||| NN
distribution  ||| S:2751 E:2764 ||| NN
systems ||| S:2764 E:2771 ||| NNS
.  ||| S:2771 E:2773 ||| .
